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Background
Health anxiety and medically unexplained symptoms cost the
National Health Service (NHS) an estimated £3 billion per year in
unnecessary costs with little evidence of patient benefit.
Effective treatment is rarely taken up due to issues such as
stigma or previous negative experiences with mental health
services. An approach to overcome this might be to offer
remotely delivered psychological therapy, which can be just as
effective as face-to-face therapy and may be more accessible
and suitable.
Aims
To investigate the clinical outcomes and cost-effectiveness of
remotely delivered cognitive–behavioural therapy (CBT) to
people with high health anxiety repeatedly accessing
unscheduled care (trial registration: NCT02298036).
Method
A multicentre randomised controlled trial (RCT) will be
undertaken in primary and secondary care providers of
unscheduled care across the East Midlands. One hundred and
forty-four eligible participants will be equally randomised to
receive either remote CBT (6–12 sessions) or treatment as
usual (TAU). Two doctoral research studies will investigate
the barriers and facilitators to delivering the intervention and the
factors contributing to the optimisation of therapeutic outcome.
Results
This trial will be the first to test the clinical outcomes and cost-
effectiveness of remotely delivered CBT for the treatment of
high health anxiety.
Conclusions
The findings will enable an understanding as to how this
intervention might fit into a wider care pathway to enhance
patient experience of care.
Declaration of interest
None.
Copyright and usage
© The Royal College of Psychiatrists 2016. This is an open
access article distributed under the terms of the Creative
Commons Non-commercial, No Derivatives (CC BY-NC-ND)
licence.
Medically unexplained symptoms cost an estimated £3 billion per
year of incremental unnecessary costs to the National Health
Service (NHS) in England.1 Much of this is consumed through in-
patient admission, general practitioner (GP) consultations, pre-
scriptions and unscheduled care use. Health anxiety often
contributes to an increased use of services2,3 because it results in
increased reassurance seeking behaviour which in turn can
maintain health anxiety.4 Reducing costs of unscheduled emer-
gency care, particularly admissions to acute hospitals, is part of
the quality premium for each clinical commissioning group
(CCG).5
In a recent meta-analysis of seven randomised controlled trials
(RCTs) comparing cognitive–behavioural therapy (CBT) v. treat-
ment as usual (TAU) with follow-up, CBT was effective on health
anxiety and depression, and the results were robust to publication
bias.6 Most RCTs were conducted in psychological treatment or
medical out-patient clinic settings. A recent large multicentre RCT
found reductions in health anxiety that were maintained for at
least 2 years.7 Furthermore, the reduction in care use covered the
cost of therapy provision, although the additional costs of screen-
ing for 28 000 people with health anxiety in medical clinics were
not covered.8
The focus of Department of Health CCG policy and Improving
Access to Psychological Therapies (IAPT) work is to prevent
emergency care use through action in primary care5,9 or failing
that by preventing emergency hospital admissions through alter-
native service provision enacted through emergency care services.5
Currently, there are no RCTs of the clinical or cost-effectiveness of
CBT for health anxiety in patients seeking urgent treatment from
primary or emergency care settings despite there being a high
prevalence of health anxiety in these settings and health-anxious
patients representing a significant proportion of emergency care
users.10 At present IAPT provides CBT for health anxiety but only
0.1–0.4% of patients seen by IAPT services in England have health
anxiety11,12 suggesting a low uptake of these services by patients and
referrers. Recently completed work from the Collaboration for
Leadership in Applied Health Research and Care Nottinghamshire,
Derbyshire and Lincolnshire (CLAHRC-NDL) regular attenders’
project provides an explanation. The project interviewed 15
participants with health anxiety or related problems, 33 GPs and
other members of primary care staff and 3 CBT therapists.
This work found that there was considerable stigma among
these participants in relation to attending mental health services.
The stigma was such that some GPs would not refer some patients.
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When patients did go, they reported that mental health services
were inflexible, made little attempt to engage them and were
unable or unwilling to meet their needs (M. Stubley, personal
communication, 2015).
Remotely delivered psychological therapy is a more accessible
approach that has been used to address health anxiety effec-
tively.13,14 Increasingly, remote delivery of psychological treatment
by telephone or the internet can be a successful way of engaging
groups of patients with mental health problems where either anxiety
or stigma among groups with physical and mental health problems
prevents their attendance at IAPT or mental health services.13–15
Potentially it is an efficient use of time and resources because
neither the therapists nor the patients have to travel to appoint-
ments, it is easy to arrange at a mutually convenient time and even
people living in remote areas can receive treatment. On the other
hand, there are potentially a range of challenges with such an
approach such as lack of access to or confidence with technology,
reliability of connectivity, data protection and privacy.15
A systematic review showed that for people with depression and
anxiety, telephone-delivered or internet-delivered psychological
treatment can be just as effective as face-to-face treatment, although
some techniques require adaptation.16 At present, remotely deliv-
ered therapy over the internet tends to be computer-led self-help
therapy for volunteers with health anxiety with minimal therapist
contact.13 People who attend urgent care with health anxiety often
do not understand that they may have health anxiety when they
would meet diagnostic criteria for it so they are very unlikely to
make use of computer-led self-help therapy. Therefore, there is a
need to develop interventions that could be delivered to people who
attend unscheduled care with health anxiety. The effectiveness of
the treatment delivered through technology is thought to be
dependent on the same factors that generally determine the
outcome of psychological therapy, the quality of the therapeutic
relationship between therapist and patient, competency and
adherence to the therapeutic approach, pace and duration of
treatment.16–17 This highlights the significance of a strong ther-
apeutic relationship. Video-conferencing software may be an
approach that enables an experience closer to face to face than
most computer-oriented therapy. As such, there is potential for
closer therapeutic relationships and, possibly, better or more cost-
effective outcomes.
The primary aim of the study was to test the clinical outcomes
and cost-effectiveness of remotely delivered CBT to repeat users of
unscheduled care services who have severe health anxiety. The
findings will inform whether remotely delivered CBT is effective
in reducing health anxiety and use of health services. Given that
there is already evidence that the participants in the current study
would usually be unwilling to attend face-to-face treatment, the
design of choice is a comparison of remotely delivered CBT
v. TAU rather than face-to-face delivered CBT. Thus the study
consists of the following objectives:
1 To determine the clinical outcomes and cost-effectiveness of
offering 6–12 sessions of remotely delivered CBT for health
anxiety in repeated users of unscheduled primary or secondary
care for physical symptoms without an underlying physical
health cause who have high health anxiety v. TAU.
2 To explore the feasibility and usefulness of research on
implementation processes by identifying the barriers and
enablers to delivering such remote treatment and how such
treatment might fit into a wider care pathway to enhance patient
experience of care.
Method
Study design
The study is a two-arm parallel group, longitudinal, mixed
methods, single-masked, multicentre RCT investigating the clin-
ical outcomes and cost-effectiveness of remotely delivered CBT in‐
tervention v. TAU. Participants randomised to the trial will be
allocated to one of two arms:
1 In the remote CBT intervention arm participants will receive
6–12 sessions of CBT delivered remotely; this will be via video
calling or over the telephone in addition to the usual care they
receive.
2 In the TAU arm participants will continue to consult with
their GP and other health providers they would normally
approach.
Participants in both arms will be followed up 3, 6, 9 and 12
months after the baseline assessment.
Participants
The study will be a multicentre study undertaken in primary and
secondary care centres across five regions in the East Midlands:
Nottinghamshire, Leicestershire, Derbyshire, Northamptonshire
and Lincolnshire. Participants will be recruited from
unscheduled primary and secondary care services in each centre.
This will include emergency departments and GP practices where
same-day urgent appointments are offered. This may also extend to
recruiting from walk-in centres, out-of-hours services and
out-patient clinics. Participants will be selected based on the criteria
below.
Inclusion criteria
. Two or more consultations, referrals or hospital admissions
with any provider of unscheduled care (including urgent
same-day appointments at their general practice) in the past
12 months for symptoms such as cardiac, respiratory,
neurological, gastrointestinal or genitourinary problems not
attributed to identified pathology.
. A score of 18 or above on the Health Anxiety Inventory
(HAI).18 This is the clinical cut off for severe health anxiety.
. Aged 18 years and over.
. Sufficient understanding of English (spoken and written) to
enable full engagement in the intervention.
. Able and willing to give oral and written informed consent to
participate in the study (Fig.1).
Exclusion criteria
. Presence of a pathological medical condition requiring further
assessment or acute management. This criterion aims to prevent
obstruction of medical treatment through the addition of
psychological therapy, where the cause of symptoms or outcome
of investigations remains unclear. However, those with a
diagnosed ongoing chronic medical condition would not be
excluded.
. Pregnancy.
. Severe mental illness such as schizophrenia, bipolar disorder,
severe major depressive episode or eating disorder.
. At immediate risk of harm to themselves or other people
through their mental state.
. A diagnosis of organic mental disorder such as dementia,
delirium, substance use disorder or organic mood disorder.
. Receiving specialist mental health intervention or have done
within the past 6 months. This will enable a clearer indication
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of the intervention’s impact on functioning over and above
other treatments.
. Significant intellectual disability that is moderate to severe
or to the extent that engagement in the intervention is not
possible.
Referring clinicians will approach patients meeting eligibility
criteria, and seek consent to be contacted by the study researchers.
Potential participants who provide written or verbal consent to
be contacted by the research team will then be telephoned by a
researcher. Information will be provided about the study and
consent to carry out eligibility screening will be sought. If the
potential participant wishes to continue, an eligibility screening will
be carried out. A person will be deemed eligible if they have had two
or more consultations with any provider of unscheduled services in
the past 12 months and a score of 18 or more on the HAI. If eligible,
the researcher will then arrange an assessment interview with the
potential participant. At the interview, oral and written consent will
be sought and the baseline assessment conducted. A brief explana-
tion of health anxiety and its impact on psychological and physical
health will be given to participants following screening. More
detailed explanation is given to those in the treatment arm or if
specifically requested by any participant. Individuals will be
participating in the study for 12 months from the date of
randomisation. For the implementation analysis, participants will
be interviewed separately within 18 months of their randomisation.
Staff participation will end with completion of a qualitative
interview.
Randomisation
Following eligibility screening and baseline assessment the
researcher will enter the participant’s details onto a web-based
randomisation system. The arm to which a participant is assigned
will be determined by a computer-generated pseudo random code
using random permuted blocks of varying size, created by the
Nottingham Clinical Trials Unit (CTU) in accordance with their
standard operating procedure and held on a secure server.
Participants will be allocated with equal probability to each
treatment armwith stratification by region. Only the trials manager,
or their nominee, will have password access to the unmasked
randomisation data. The researchers responsible for collecting the
baseline and outcome data will remain masked to randomisation
Randomly allocated (n =144)
Treatment as usual (TAU) 
If eligible written consent obtained and 
baseline assessment carried out
Study team makes initial contact for
eligibility screening
>2 consultations with unscheduled care
in past 12 months and >18 on HAI 
Remote CBT intervention 
(6–12 sessions) 
Patients screened and selected by clinicians
Follow-up assessments at 3, 6, 9 and 12 months 
Not eligible or declines to 
participate in the study
Study flyer and participant information 
sheet provided and consent for study team 
to make contact
Declines to participate in 
the study
Not eligible or declines to 
participate in the study
Fig. 1 Study ﬂow chart comparing remotely delivered cognitive–behavioural therapy (CBT) v. treatment as usual (TAU) for high utilisers of
healthcare with high health anxiety. HAI, Health Anxiety Inventory.
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until data collection has been completed. Participants themselves
and the CBT practitioners will not be masked to treatment group.
Investigators may identify the treatment of participants through
password-protected access; however, this will only be done at the
end of the trial or in the event of a medical emergency or serious
adverse event. Participants may also accidentally reveal to the
researcher when obtaining outcome data that they have been
receiving the remote CBT intervention. If this occurs then any
case of un-masking will be reported and a written account of the
reason for un-masking will also be made. Following data collection
an analysis will be completed to determine if incidences of
un-masking were equal in the two treatment groups.
Recruitment of staff
Health professionals and managers of services from different
service settings and localities who are involved in the study will be
approached by a doctoral researcher and asked whether they wish
to participate in a qualitative interview.
Interventions
Following baseline assessment and confirmation of eligibility,
participants will be randomly allocated to one of two treatment
arms: (1) remote CBT intervention (in addition to usual treatment)
or (2) TAU only.
Remotely delivered CBT intervention
Participants allocated to the remote CBT intervention will be
provided with a detailed information sheet about the remote CBT
intervention and contacted by a CBT practitioner within 10 days of
randomisation. A team of experienced CBT practitioners will
deliver CBT for health anxiety remotely using a treatment manual
developed from the CHAMP study.7 Clinical supervision will be
facilitated by the lead therapist from the CHAMP study (H.T.)
trained and experienced in the engagement of high service utilisers
and delivery of CBT for health anxiety. The Revised Cognitive
Therapy Scale (CTS-R)19 will be used to assess therapist competence
and treatment integrity. It will also be used to maintain the standard
of therapy provided, as assessment results will inform supervision.
Two randomly selected sessions will be assessed for each therapist
by the supervisor (H.T.) and feedback given for areas of strength
and areas for development. Six to twelve sessions will be offered,
with the addition of follow-up sessions if required. The number of
sessions will be dependent on the pace of engagement with the
participant and in line with patient need. The intervention will
address the symptoms of health anxiety from a cognitive–beha-
vioural perspective. This will include undoing patterns of thought
and behaviour that maintain health anxiety. For example, safety-
seeking behaviours such as reassurance-seeking or phobic avoid-
ance aim to reduce worry, but can often fuel health anxiety.
The CBT intervention will be delivered remotely via video-
calling or over the telephone depending on the participant’s
preference. Participants may also receive text message/email
reminders of CBT sessions. The system used for video-calling was
deemed to offer a secure connection and user-friendly interface
following a pilot review of available services. A contingency
management plan has been put in place to address all potential
failures in the technology. Permission will be sought to audio/video
record treatment sessions. These will be made available to all
participants as a means of consolidating learning from each session.
They will also be used for assessments of therapeutic quality and
reflection in clinical supervision meetings. Supervisory records will
also help establish any adjustments required for effective remote
delivery of therapy.
Participants will be free to continue to consult clinicians and
other healthcare providers other than the CBT therapist throughout
the intervention and after treatment completion. A discharge plan
will be developed before treatment completion. A summary of the
discharge plan will be distributed to the participant, their GP and
any other relevant healthcare providers with the participant’s
consent. Outcome data will continue to be collected after the CBT
sessions are completed until the end of the follow-up period.
TAU
Usual treatment will constitute a care plan decided by the patient
and any healthcare providers involved in their care, including
their GP. TAU will be unconstrained other than it will not be
provided by the treatment intervention therapists.
Measures
Primary outcome
The primary clinical outcome will be longitudinal change on the
short form 14-item HAI from baseline to 6 months.18
Secondary outcomes
Secondary outcomes will be any change in the following measures
from baseline to 12 months:
. Short form 14-item HAI.18
. 7-item Generalised Anxiety Disorder (GAD)20 for anxiety.
. 15-item Patient Health Questionnaire (PHQ-15)21 for somatic
distress.
. 9-item Patient Health Questionnaire (PHQ-9)22 for
depression.
. 8-item Work and Social Adjustment Scale (WSAS)23 for social
function.
. 5-item quality of life on the EQ5D-5L.24
. 36-item Short Form Health Survey (SF-36).25
. Change in the number of contacts with unscheduled or
emergency care established through an adapted and stylised
Client Service Receipt Inventory (CSRI).26
Other measures
At the baseline assessment only, the participant will also be
interviewed using the research version of the Structured Clinical
Interview for DSM-5 (SCID-5).27 This will determine if people have
mental disorders that exclude participation in the study and record
the absence or presence of somatisation disorders, depressive
disorders and anxiety disorders.
To elicit the participant’s views of treatment, a modified
version of a self-rated 5-item scale will be given at completion of
treatment,28 along with some semi-structured questions about the
remote CBT to evaluate treatment satisfaction. The questionnaire
will be posted out to all participants who receive any CBT sessions
including those who complete the treatment and those who
terminate treatment before completion. The questionnaire will
be sent out by the project administrative support officer who will
not be masked to treatment allocation.
All baseline assessments will be carried out face to face or over
the telephone (if requested by the participant) by the study
researchers. All the measures have established reliability, validity
and history of use in clinical NHS settings. Follow-up assessments
will be carried out over the telephone, email, via video-calling or by
post at all time points depending on the participant’s preference. A
copy of the baseline assessments and follow-up questionnaires can
be provided by contacting the corresponding author.
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Outcomes collated by CBT practitioners
The CBT practitioners will collate brief measures of outcome,
patient experience and therapist experience at each session of
therapy:
. Short Form HAI18
. Outcome Rating Scale (ORS)29
. Session Rating Scale (SRS)30
. Working Alliance Inventory-Short Revised (WAI-SR).31
CBT practitioners will collate and have access to data collated
from patients allocated to the remote CBT arm.
Statistical analysis
The analysis will be conducted on an intention-to-treat basis.
Exploratory analysis for both primary and secondary outcomes
will be conducted first. Given that the primary outcome variable
will be repeatedly measured, multilevel modelling will be per-
formed to quantify the treatment effects with patient as a level 2
unit. The time, treatment status and treatment × time interactions
and baseline measurements will be included as covariate. Second-
ary outcomes will be analysed in a similar way. Any skewed
outcome variables will be transformed for multilevel modelling.
The analysis will thus broadly follow the same approach as the
CHAMP study.7
Missing values in all outcomes will be checked and reported
across treatment group and follow-up time. As the outcome will be
repeatedly measured, a two-level logistic regression with patients as
level 2 unit will be performed to test the influence of treatment
status and baseline measures on outcome missingness. The missing
value patterns and the results from multilevel logistic regression
modelling will be used to inform missing value imputation under
missing at random (MAR) assumption. Because multilevel model-
ling will be used to test treatment effects for all outcome variables
that will be repeatedly measured, missing values could be auto-
matically taken into account under MAR assumption to give
sensible results. Nevertheless, as sensitivity analysis of the result
robustness to missing value, the missing values will be imputed
using multilevel modelling32 and the results based on imputed data
will be presented additionally. STATA 14 and REALCOM-
IMPUTE software will be used to impute missing values by
means of the Markov chain Monte Carlo (MCMC) approach for
multilevel data.
Previously identified mediators and moderators of face-to-face
delivered CBT will be examined including the presence or absence
of depression, other comorbid mental and physical disorders,
gender and severity of health anxiety at baseline.6 In addition we
will examine factors considered to affect utilisation and confidence
in the use of internet technology such as age and socioeconomic
deprivation.
Sample size and calculation
Based on the CHAMP study results, which showed that the mean
HAI score for CBT and TAU groups were 24.9 (s.d.=4.2) and 25.1
(s.d.=4.5) respectively at baseline and 17.7 (s.d.=8.0) and 22.6
(s.d.=6.8) respectively at 6 months, 114 participants are required
to detect such a difference in HAI score at 6 months for a 90%
power at two-tailed significance at 0.05 level, assuming equal s.d.
(8.0) for both groups and null correlation between baseline and
follow-up measures for the purpose of being conservative. After
taking into account a 20% loss to follow-up rate, a sample size of
144 is required. Stata 13 was used to perform the power analysis.
To achieve this target sample size several strategies will be
implemented. These include the option of providing various
locations for the completion of the baseline assessments including
NHS sites, university sites and the participant’s home. Participants
will also be given various options for completing outcome
measures; this will include returning questionnaires by post,
email, telephone and video-calling.
Data monitoring
The trial will be overseen by an independent CLAHRC scientific
committee. The chief investigator has overall responsibility for the
study and shall oversee all study management.
Data on the impact of the intervention on reduction in health
anxiety and other outcome measures will not be analysed until the
end of the study period and therefore will not inform decisions to
stop the research. However, serious adverse events will be reviewed
and if there is any indication that these are linked to the intervention
consideration will be given to stopping on the advice of the scientific
committee.
Health economics
The study will be conducted from a health service and societal
perspective. It will measure patient outcome using the EQ5D-5L
and clinical outcomes where appropriate. This will enable the study
results to be reported in terms of cost utility and cost-effectiveness.
Detailed resource costing will be undertaken from a health service,
patient and societal perspective. Cost utility and cost-effectiveness
will compare remotely delivered CBT v. TAU. A detailed resource
profile will be established for the intervention v. TAU. The resource
profile will include capital cost, for example the technology and
staff, time to deliver the intervention and patient costs in each arm;
this will further include effects on employment and absence from
work because of the health anxiety and it will seek to apply an
average wage rate based on type of employment. It will in addition
record any opportunity cost in terms of time incurred by carers.
This will enable a cost profile to be calculated for each arm of the trial.
Patients with health anxiety are often high utilisers of healthcare
services and hence resources. Economic data will be collected at the
same time as the collection of self-rated questionnaires from an
adapted CSRI.26 The resource pro forma used in this study when
having the CSRI at its origin has been totally modified and custom
designed to address the needs, key issues and cost drivers in this
study. The form used in this work builds on the original CSRI and
using a similar pro forma successfully employed in a study on mood
disorder.33 Economic interviews will be conducted at baseline, 3, 6,
9 and 12 months, as the costs measured will all be accrued in a
12-month period, discounting of costs and benefits would be
unnecessary. An incremental cost-effectiveness ratio (ICER) and
cost-effectiveness acceptability curves (CEAC) will be produced for
the remote intervention v. TAU including the joint uncertainty in
differential costs and effects from the cost-effectiveness plane. The
use of both the ICER and the CEAC enables useful information to be
presented to the decision-maker in terms of the uncertainty of the
intervention. The ICER provides a ratio measure of incremental
costs and effects of the intervention over TAU, whereas the CEAC
charts the probability that the intervention will be considered cost-
effective at different thresholds of cost-effectiveness.
Implementation analysis
The implementation analysis will provide important information
on barriers and enablers to the delivery and implementation of the
intervention. It will provide specific information about the
challenges likely to be faced if the intervention is to be put into
wider practice, as well as devise specific solutions to meet these
challenges. To carry out the implementation analysis we will
utilise an organisational learning approach and develop a network
of practice, consisting of service users, the research team, GPs
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interested or involved in the study, therapists and other practi-
tioners involved in unscheduled care or psychological therapy
from participating NHS trusts.34
The analysis will be primarily qualitative with referrers and
non-referrers to the study and completers and non-completers of
treatment. A small number of additional interviews with commis-
sioners who might purchase the intervention as a service and
ecological data collected from observation and minutes from
network of practice meetings will be thematically analysed.35
Quantitative data will be utilised to inform the analysis by
potentially highlighting issues such as rates of recruitment and
attendance at treatment sessions that may inform the analysis of
barriers and drivers to the intervention. Data on these barriers and
drivers will be fed back at the network of practice meetings so that
they are addressed allowing the process of organisational learning to
optimise the intervention during the course of the study without
compromising or altering those parts of the study outlined in the
protocol that are fixed.
Results
The study has been given research ethics committee approval by the
London Riverside Ethics Committee. We currently have obtained
site approvals for Nottingham City and Nottingham County
CCG’s, Nottingham University Hospitals, Nottinghamshire
Healthcare NHS Foundation Trust, Nene and Corby CCG’s and
Northamptonshire Healthcare NHS Foundation Trust and have
commenced recruitment.Wemay recruit from other sites outside of
the East Midlands to meet recruitment targets.
Discussion
The study is funded by the National Institute of Health Research
(NIHR) Collaboration Leadership in Applied Health Research and
Care (CLAHRC) East Midlands and matched funding from NHS
Partners. The funding allows a unique opportunity to be able to
carry out an RCT to test the clinical outcomes and cost-effectiveness
of remotely delivered CBT for repeated users of unscheduled care.
There are no previous trials which have incorporated the use of
video conferencing CBT for the treatment of health anxiety.
CLAHRC East Midlands identified that reduction in primary and
secondary unscheduled care use was an NHS priority. The CHAMP
study provided evidence that CBT for health anxiety was effective
for at least 2 years,7 but the screening of patients they employed was
impractical. However, patients with health anxiety do not use
readily available conventional face-to-face CBT services for health
anxiety but in other research have engaged with remotely delivered
CBT.13–14
Through previous work with people who have medically
unexplained symptoms in primary care and with persistent frequent
attenders in primary care36 the research team recognised that with
careful use of language for both patients and clinicians it may be
possible to find an acceptable form of words to recruit high utilisers
of urgent care with high health anxiety. The research team
constructed a network of practice from the outset of the study
including a number of service users and members of the public with
and without health anxiety and a variety of clinicians from the East
Midlands and nationally who refer or manage people with health
anxiety either face to face or remotely. Through an iterative process
of using expertise by experience, we have found ways of describing
the study in a way that has enabled us to recruit both referrers and
patients into the study.
A CLAHRC study such as this must evaluate interventions as
they would be delivered in clinical practice if they were to be
adopted as part of routine care. As a result the design of the study
examines clinical outcomes and cost-effectiveness compared with
any routine care offered rather than efficacy of the intervention by
utilising a control for attentional effects of a therapist or one that
prevents the control group receiving any intervention that the
health service wishes to offer. However, should remotely delivered
CBT be effective compared with TAU, a non-inferiority RCT
comparing it with face-to-face delivered CBT in those people with
health anxiety willing to receive either approach may be warranted
to determine the relative merits of both approaches. The outcome
measures were selected to include those that IAPT services would
routinely employ for patients with health anxiety as well as those
examining cost-effectiveness and for the completion of the doctoral
research. Thus the estimates of the clinical outcomes and cost-
effectiveness as well as the implementation analysis will provide a
direct estimate of the overall benefits and drawbacks of the
approach should it be delivered routinely, allow a comparison
with the outcomes of people with health anxiety who do receive
routine IAPT treatment as well as provide data on challenges that
remain to be addressed. The approach also requires proficiency in
English and may need to be adapted for non-English speakers. A
pragmatic RCT would have as few exclusion criteria as possible, yet
the study excludes people with serious mental illness, eating dis‐
order and substance use disorders; all of the above require a dif‐
ferent clinical approach to the treatments being tested in the study.
Unipolar, mild-to-moderate depressive episodes, other anxiety dis‐
orders or stable physical illnesses are not exclusions to the study as
they are readily addressed by the intervention and are necessary to
include if the study is pragmatic enough for use in clinical practice.
The study is multicentre but medium sized. A larger sample
recruited from areas outside the East Midlands might increase the
precision of our estimates of the effectiveness of the intervention
v. TAU and the generalisability of the findings, but there are finite
resources restricting the size of the study but not necessarily
recruitment from outside the East Midlands. Thus the study has
been adopted by the Clinical Research Network, and there are
ongoing discussions with some more geographically distant sites
in England; such recruitment will help the study to achieve its
recruitment targets and increase the generalisability of its findings
to routine healthcare across England.
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